Results of clinical trials of a trivalent vaccine for horses

We have developed a trivalent vaccine made from the SV/69 strain of the Rhinopneumonia virus (RHIV), the bacteria strains of Salmonella abortus equi BN-12 - the causative agent of Salmonella abortion and Streptococcus equi N-34 - the causative agent of the horse strangles. Preclinical laboratory studies of the immunogenicity of the vaccine in linear and outbred mice showed that the preparation protects against experimental infection with the Rhinopneumonia virus by 88.8%, from the causative agents of Salmonella abortion and horse strangles by 100%. There were carried out clinical trials of a trivalent inactivated vaccine with a centrifuge strain Bacillus subtilis TNP-3 as an immunomodulator in order to specifically prevent salmonella abortion, rhinopneumonia and horse strangles. Clinical trials were carried out on horses in the Central regions of Yakutia. The business output of foals was 50.2% in the republic. The business yield in immunized mares was 76,0 % and in unvaccinated mares only 38,0 % in a controlled production trial at the "Uyruye" agricultural production complex. Consequently, immunization of mares with trivalent vaccine increased the reproduction rate by 38,0 %. Results of extensive production tests on 2,568 heads of herd horses confirmed the data of preclinical laboratory studies of immunogenicity in linear and outbred mice. The trivalent vaccine against rhinopneumonia, salmonella abortion and horse strangles stimulates immunobiological reactivity, induces the synthesis of specific antibodies in high titers and increases the business yield of foals from 18,0 to 38,0 %. The vaccine is highly effective and can provide recovery of disadvantaged settlements.